These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8637487)

  • 1. Genetic testing for familial cancer. A clinician's perspective.
    Hilden JM; Watterson J; Garr CL
    Minn Med; 1996 Apr; 79(4):29-32. PubMed ID: 8637487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes.
    Moley JF
    Annu Rev Med; 1997; 48():409-20. PubMed ID: 9046972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies].
    Stuhrmann M
    Fortschr Med; 1995 Dec; 113(35-36):503-6. PubMed ID: 8582691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
    Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
    Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy.
    Dang GT; Cote GJ; Schultz PN; Khorana S; Decker RA; Gagel RF
    Mol Cell Probes; 1999 Feb; 13(1):77-9. PubMed ID: 10024437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.
    Wells SA; Chi DD; Toshima K; Dehner LP; Coffin CM; Dowton SB; Ivanovich JL; DeBenedetti MK; Dilley WG; Moley JF
    Ann Surg; 1994 Sep; 220(3):237-47; discussion 247-50. PubMed ID: 7916559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
    Belli S; Storani ME; Dourisboure RJ; Podestá EJ; Solano AR
    Medicina (B Aires); 2003; 63(1):41-5. PubMed ID: 12673960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
    Miyauchi A; Egawa S; Futami H; Kuma K; Obara T; Yamaguchi K
    Jpn J Cancer Res; 1997 Jun; 88(6):527-31. PubMed ID: 9263528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
    Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
    JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families.
    McMahon R; Mulligan LM; Healey CS; Payne SJ; Ponder M; Ferguson-Smith MA; Barton DE; Ponder BA
    Hum Mol Genet; 1994 Apr; 3(4):643-6. PubMed ID: 7915166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.